Literature DB >> 23271318

A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved.

Ana Espinosa1, Montserrat Alegret, Sergi Valero, Georgina Vinyes-Junqué, Isabel Hernández, Ana Mauleón, Maitée Rosende-Roca, Agustín Ruiz, Oscar López, Lluís Tárraga, Mercè Boada.   

Abstract

The most recent studies about mild cognitive impairment (MCI) are focused on the search for factors that make patients more vulnerable to conversion to dementia, mainly Alzheimer's disease (AD). The aim of this study was to determine which neuropsychological test performances, including episodic memory profiles, and genetic risk factors (APOE ε4) better predict early conversion to dementia among the four MCI subtypes. Data from 550 MCI patients were analyzed for the purpose of this study and were classified according to Petersen's criteria (2004), and also taking into account the absence (probable MCI) or presence (possible MCI) of comorbidities that could explain cognitive deficits. MCI cases were divided into Probable amnestic (Pr-aMCI) (n = 115), probable non-amnestic (Pr-naMCI) (n = 37), possible amnestic (Pss-aMCI) (n = 234), and possible non-amnestic (Pss-naMCI) (n = 164), single or multiple domain. In the whole MCI sample, regression analysis showed that low performances on Orientation, Verbal Delayed Recall of the Word List Learning test from WMS-III, and Luria's Clock test were associated with conversion to dementia, independently of APOE ε4 allele. Cox proportional-hazards showed that the Probable MCI subtype, presence of storage memory impairment, multiple domain condition, and presence of at least one ε4 allele increased the risk of conversion to dementia. Multivariate survival and Kapplan-Meier analyses showed that the Pr-aMCI with storage memory impairment had the most and closest risk of conversion to dementia. In conclusion, the Pr-aMCI subset of patients had 8.5 times more risk of converting to dementia than the Pss-naMCI group, who displayed the slowest conversion rate to dementia.

Entities:  

Mesh:

Year:  2013        PMID: 23271318     DOI: 10.3233/JAD-122002

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  60 in total

1.  Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment.

Authors:  Montserrat Alegret; Gemma Cuberas-Borrós; Ana Espinosa; Sergi Valero; Isabel Hernández; Agustín Ruíz; James T Becker; Maitée Rosende-Roca; Ana Mauleón; Oscar Sotolongo; Joan Castell-Conesa; Isabel Roca; Lluís Tárraga; Mercè Boada
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Training gains and transfer effects after mnemonic strategy training in mild cognitive impairment: A fMRI study.

Authors:  Sharon S Simon; Benjamin M Hampstead; Mariana P Nucci; Fábio L S Duran; Luciana M Fonseca; Maria da Graça M Martin; Renata Ávila; Fábio H G Porto; Sônia M D Brucki; Camila B Martins; Lyssandra S Tascone; Edson Amaro; Geraldo F Busatto; Cássio M C Bottino
Journal:  Int J Psychophysiol       Date:  2019-03-29       Impact factor: 2.997

3.  Dyadic Analysis of Illness Perceptions Among Persons with Mild Cognitive Impairment and Their Family Members.

Authors:  Jennifer H Lingler; Lauren Terhorst; Richard Schulz; Amanda Gentry; Oscar Lopez
Journal:  Gerontologist       Date:  2015-04-15

4.  Tiaobu Xinshen Recipe () Improved Mild Cognitive Impairment of Alzheimer's Disease Patients with Xin (Heart) and Shen (Kidney) Deficiency.

Authors:  Zhi-Ying Lin; Tian-Wen Huang; Jun-Shang Huang; Guan-Yi Zheng
Journal:  Chin J Integr Med       Date:  2019-11-27       Impact factor: 1.978

5.  Plasma phospholipids identify antecedent memory impairment in older adults.

Authors:  Mark Mapstone; Amrita K Cheema; Massimo S Fiandaca; Xiaogang Zhong; Timothy R Mhyre; Linda H MacArthur; William J Hall; Susan G Fisher; Derick R Peterson; James M Haley; Michael D Nazar; Steven A Rich; Dan J Berlau; Carrie B Peltz; Ming T Tan; Claudia H Kawas; Howard J Federoff
Journal:  Nat Med       Date:  2014-03-09       Impact factor: 53.440

Review 6.  18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Gabriel Martínez; Robin Wm Vernooij; Paulina Fuentes Padilla; Javier Zamora; Leon Flicker; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

Review 7.  18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Gabriel Martínez; Robin Wm Vernooij; Paulina Fuentes Padilla; Javier Zamora; Leon Flicker; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

Review 8.  Strategies for dementia prevention: latest evidence and implications.

Authors:  Gopalkumar Rakesh; Steven T Szabo; George S Alexopoulos; Anthony S Zannas
Journal:  Ther Adv Chronic Dis       Date:  2017-06-27       Impact factor: 5.091

Review 9.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

Review 10.  18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Gabriel Martínez; Robin Wm Vernooij; Paulina Fuentes Padilla; Javier Zamora; Xavier Bonfill Cosp; Leon Flicker
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.